HBSP (USA)
-
Merck: La administración de Vioxx (D)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S05Knowledge and CommunicationStarting at €5.74
-
Pfizer: Letter from the Chairman (B)
Simons, Robert L.; Rosenberg, KathrynCase HBS-110004-EAccounting and ControlThis case continues the story begun in "Pfizer: A Letter From The Chairman" (HBS No. 9-110-003), revealing the letter Chairman and CEO Jeff Kindler wrote for the 2008 Annual Report.Starting at €5.74
-
Pfizer: Letter from the Chairman (A) and (B), Teaching Note
Simons, Robert L.; Rosenberg, KathrynTeaching Note HBS-110067-EAccounting and ControlTeaching Note for 110003 and 110004.Starting at €0.00
-
Sydney IVF: Stem Cell Research, Teaching Note
Simons, Robert L.; Rosenberg, KathrynTeaching Note HBS-110092-EStrategyTeaching Note for 109017.Starting at €0.00
-
Pathfinder Capital
Sahlman, William A.; Janower, AndrewCase HBS-396067-EEntrepreneurshipTwo former consultants have raised a search fund and are looking for a company to buy and run. After eight months of looking at deals, they have just signed a letter of intent to buy the second largest book retail chain in Canada in a turnaround situation. They must now decide whether to go through with the deal and, if so, how to raise the necessary financing.Starting at €8.20
-
Khosla Ventures: Biofuels Strategy
Lassiter, Joseph B.; Sahlman, William A.; Wagonfeld, Alison BerkleyCase HBS-809004-EFinanceBy 2008, a number of the firm's early cleantech investments were showing promise, and the companies were starting to need significantly more money to create the massive scale required in the energy sector. As Khosla thought about the hundreds of millions of dollars required by his portfolio companies, he wondered how he should position his firm at this stage of development. Should Khosla develop a new fund that focused on later-stage investments?...Starting at €8.20
-
Foro Energy (A)
Lassiter, Joseph B.; Sahlman, William A.; McQuade, JamesCase HBS-812136-EEntrepreneurshipForo Energy developed proprietary and patent-pending fiber-laser technologies that could disrupt existing processes and services for the exploration and production of oil and natural gas. These breakthrough laser technologies were protected by a strong intellectual property (IP) portfolio, which provided Foro with the flexibility to pursue a number of different business models. The market potential for oilfield applications was large, as global s...Starting at €8.20
-
TerraPower
Sahlman, William A.; Nanda, Ramana; Lassiter, Joseph B.; McQuade, JamesCase HBS-813108-EEntrepreneurshipJohn Gilleland, CEO of TerraPower, returned to his office after a lengthy meeting with potential investors. It was October 2012, and TerraPower was in the process of raising a $200M Series C round to finance the ongoing development of its next-generation nuclear reactor. Though early in the fundraising process, Gilleland noted that this most recent conversation was similar to conversations with other interested cleantech growth equity investors. ...Starting at €8.20
-
WebTracker (Spanish version)
Sahlman, William A.; Roberts, Michael J.Case HBS-917S02EntrepreneurshipThis case describes the evolution of a tech startup, WebTracker, and focuses on the decision of two aspiring entrepreneurs (Julie Stern and Mark Foster) who have just received offers for Venture Capital (VC) financing for the company. These offers, or term sheets, are similar in some respects and different in others. The two firms offering financing are also different. The heart of the case involves comparing these term sheets and determining the...Starting at €8.20
-
Managing Vioxx (A) (Spanish version)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S02Strategy(B) evidence of life-threatening side effects, (C) decision options, (D) announcement to withdraw Vioxx, (E) reaction by patients, shareholders, media, and regulators, (F) Merck fights back, and (G) wrap-up. At the end of the case series, students may conclude that doing the right thing sometimes requires very hard choices.Starting at €8.20